Crescita TherapeuticsTSX:CTX 20 Buyback Yield % is 1.22 as of Jul. 12, 2026, which is 31% above its 10-year median of 0.93. GuruFocus rates TSX:CTX with a GF Score™ of 20/100 and a GF Value™ of C$0.68 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 290 Drug Manufacturers companies, Crescita Therapeutics ranks better than 84.48% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Crescita Therapeutics Buyback Yield % Related Terms
Crescita Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Crescita Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescita Therapeutics Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Crescita Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescita Therapeutics (TSX:CTX) has a Buyback Yield % of 1.22 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Crescita Therapeutics and its competitors. This is 31% above median its historical median of 0.93. According to the industry distribution chart, Crescita Therapeutics ranks #45 out of 290 companies in the Drug Manufacturers industry, placing it in the top 15.5%.
Is Crescita Therapeutics' Buyback Yield % too high?
Crescita Therapeutics' current Buyback Yield % of 1.22 is 31% above median its 10-year median of 0.93. Based on the distribution chart, Crescita Therapeutics ranks #45 out of 290 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Crescita Therapeutics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Crescita Therapeutics ranks #45 out of 290 companies for Buyback Yield %. This places Crescita Therapeutics in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Crescita Therapeutics and its competitors. Crescita Therapeutics's current Buyback Yield % is 1.22, which is 31% above median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Crescita Therapeutics (TSX:CTX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.68, compared to a current price of C$0.79 — trading 16.2% above its estimated fair value. The current Buyback Yield % is 1.22, which is 31% above median its 10-year median of 0.93. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current Buyback Yield % is 1.22 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crescita Therapeutics (TSX:CTX) Overvalued in 2026?
Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued.
The current stock price of C$0.79 is trading 16.2% above its estimated GF Value™ of C$0.68.
GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.
Key valuation signals for TSX:CTX:
Buyback Yield %: 1.22 (31% above median its 10-year median of 0.93)
GF Value™: C$0.68 vs. price of C$0.79 (16.2% above fair value)
No single metric tells the full story. See the TSX:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score
Get the complete analysis for TSX:CTX
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CTX has been successfully added to your 
